The combination of sephedex and docetaxel used in intervention for clinical treatment of primary liver cancer
10.3969/j.issn.1002-1671.2017.05.024
- VernacularTitle:葡聚糖微球联合多西紫杉醇介入治疗原发性肝癌的临床疗效
- Author:
Jingxian LI
;
Yanping JIANG
;
Jiaping WANG
;
Li GUO
;
Li ZHU
;
Rui LIU
;
Ruimin ZHAO
;
Yuyun TONG
;
Yuanxi JIAN
- Keywords:
sephedex;
docetaxel;
iodinated oil;
primary liver cancer;
transcatheter arterial chemoembolization
- From:
Journal of Practical Radiology
2017;33(5):739-741,753
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical efficacy of the combination of sephedex and docetaxel used in transcatheter arterial chemoembolization (TACE) for clinical treatment of primary liver cancer.Methods 120 patients with primary liver cancer in our hospital were divided into the experimental group and the control group randomly and equally, the 60 cases in experimental group were treated with sephedex suspensoid (Sephedex, G-50, 300-500 μm) and docetaxel-iodized oil, while other 60 cases in control group were treated with docetaxel-iodized oil suspension liquid.Results The success rate of surgical intubation in the two groups was 100%.After an average follow-up of 12 months, the postoperative tumor diameter of the experimental group was reduced by (4.4±1.4) cm, while that of the control group was (1.8±1.0) cm;The overall response rate was 70% in the experimental group in contrast to 30% in the control group;the alpha fetal protein (AFP) value was decreased by (33.2±15.2) μg/L in the experimental group and (10.4±9.8) μg/L in the control group.Conclusion The combination of sephedex, docetaxel suspensoid and iodized oil shows great potential in TACE treatment of primary liver cancer, from which the treatment effect can be improved significantly.
